QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kwok, J. C. Articles by Richardson, D. R. Search for Related Content PubMed PubMed Citation Articles by Kwok, J. C. Articles by Richardson, D. R.

Examination of the Mechanism(s) Involved in Doxorubicin-Mediated Iron Accumulation in Ferritin: Studies Using Metabolic Inhibitors, Protein Synthesis Inhibitors, and Lysosomotropic Agents

Children's Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, Randwick, Sydney, New South Wales, Australia

Anthracyclines are potent anticancer agents, but their use is limited by cardiotoxicity at high cumulative doses. The mechanisms involved in anthracycline-mediated cardiotoxicity are still poorly understood, but numerous investigations have indicated a role for iron in this process. Our previous studies using neoplastic and myocardial cells showed that anthracyclines inhibit iron mobilization from the iron storage protein, ferritin, resulting in marked accumulation of ferritin-iron. Although the process of ferritin-iron mobilization is little understood, catabolism of ferritin by lysosomes may be a likely mechanism. Because anthracyclines have been shown to accumulate in lysosomes, this latter organelle may be a potential target for these drugs. The present study demonstrated, using native polyacrylamide gel electrophoresis-⁵⁹Fe autoradiography, that ferritin-⁵⁹Fe mobilization is an energy-dependent process that also requires protein synthesis. Depression of lysosomal activity via the enzyme inhibitors E64d [(2S,3S)-trans-epoxysuccinyl-L-leucylamido-2-methylbutane ethyl ester] and leupeptin or the lysosomotropic agents ammonium chloride, chloroquine, and methylamine resulted in a 3- to 5-fold increase in ⁵⁹Feferritin accumulation compared with control cells. In addition, the proteasome inhibitors N-benzoyloxycarbonyl (Z)-Leu-Leuleucinal (MG132) and lactacystin also significantly increased ⁵⁹Fe-ferritin levels compared with control cells. These effects of lysosomotropic agents or inhibitors of lysosomal activity were comparable with that observed with the anthracycline doxorubicin. Collectively, our study indicates a role for lysosomes and proteasomes in ferritin-iron mobilization, and this pathway is dependent on metabolic energy and protein synthesis. Furthermore, the lysosome/proteasome pathway may be a novel anthracycline target, inhibiting iron mobilization from ferritin that is essential for vital iron-requiring processes such as DNA synthesis.

Address correspondence to: Dr. D.R. Richardson, Children's Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, P.O. Box 81, High Street, Randwick, Sydney, NSW 2031, Australia. E-mail: d.richardson{at}ccia.org.au

This article has been cited by other articles:

				F. Liang, Y. Luo, Y. Dong, C. D. Walls, J. Liang, H.-Y. Jiang, J. R. Sanford, R. C. Wek, and Z.-Y. Zhang Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase J. Biol. Chem., April 18, 2008; 283(16): 10339 - 10346. [Abstract] [Full Text] [PDF]

				X. Xu, R. Sutak, and D. R. Richardson Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking Mol. Pharmacol., March 1, 2008; 73(3): 833 - 844. [Abstract] [Full Text] [PDF]

				M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347. [Abstract] [Full Text] [PDF]

				X. Lu, S. Liu, and T. B. Kornberg The C-terminal tail of the Hedgehog receptor Patched regulates both localization and turnover Genes & Dev., September 15, 2006; 20(18): 2539 - 2551. [Abstract] [Full Text] [PDF]

				M. Goralska, S. Nagar, L. N. Fleisher, and M. C. McGahan Differential Degradation of Ferritin H- and L-Chains: Accumulation of L-Chain-Rich Ferritin in Lens Epithelial Cells Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3521 - 3529. [Abstract] [Full Text] [PDF]

				A. Alberghini, S. Recalcati, L. Tacchini, P. Santambrogio, A. Campanella, and G. Cairo Loss of the von Hippel Lindau Tumor Suppressor Disrupts Iron Homeostasis in Renal Carcinoma Cells J. Biol. Chem., August 26, 2005; 280(34): 30120 - 30128. [Abstract] [Full Text] [PDF]

				X. Xu, H. L. Persson, and D. R. Richardson Molecular Pharmacology of the Interaction of Anthracyclines with Iron Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]